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No biomarker panel has been established for prediction of sinusoidalobstruction syndrome/veno-occlusive disease (SOS/VOD), a majorcomplication of allogeneic stem cell transplantation (alloSCT). We
compared the potential of the Endothelial Activation and Stress Index
(EASIX), based on lactate dehydrogenase, creatinine, and thrombocytes,
with that of the SOS/VOD clinical risk score of the Center for International
Blood and Marrow Transplant Research (CIBMTR) to predict SOS/VOD in
two independent cohorts. In a third cohort, we studied the impact of
endothelium-active prophylaxis with pravastatin and ursodeoxycholic acid
(UDA) on SOS/VOD risk. The cumulative incidence of SOS/VOD within
28 days after alloSCT in the training cohort (Berlin, 2013-2015, n=446) and
in the validation cohort (Heidelberg, 2002-2009, n=380) was 9.6% and
8.4%, respectively. In both cohorts, EASIX assessed at the day of alloSCT
(EASIX-d0) was significantly associated with SOS/VOD incidence
(P<0.0001), overall survival (OS), and non-relapse mortality (NRM). In con-
trast, the CIBMTR score showed no statistically significant association with
SOS/VOD incidence, and did not predict OS and NRM. In patients receiv-
ing pravastatin/UDA, the cumulative incidence of SOS/VOD was signifi-
cantly lower at 1.7% (Heidelberg, 2010-2015, n=359, P<0.0001) than in the
two cohorts not receiving pravastatin/UDA. The protective effect was most
pronounced in patients with high EASIX-d0. The cumulative SOS/VOD
incidence in the highest EASIX-d0 quartiles were 18.1% and 16.8% in both
cohorts without endothelial prophylaxis as compared to 2.2% in patients
with pravastatin/UDA prophylaxis (P<0.0001). EASIX-d0 is the first validat-
ed biomarker for defining a subpopulation of alloSCT recipients at high risk
for SOS/VOD. Statin/UDA endothelial prophylaxis could constitute a pro-
phylactic measure for patients at increased SOS/VOD risk. 
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ABSTRACT
Introduction
Sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease
(VOD), is a potentially fatal complication after allogeneic stem cell transplantation
(alloSCT).1-3 Clinical management of SOS/VOD remains challenging, since there
are no standardized predictive tools4 and diagnostic criteria are not uniform.2,4-6 The
reported incidences of SOS/VOD after alloSCT range from 5.3% to 13.7% and
vary depending on conditioning regimens, type of transplant, diagnostic criteria,
patient characteristics, and other factors.7-9  
The pathophysiology of SOS/VOD is characterized by endothelial injury caused
by the conditioning regimen as well as pre-transplant damage.1,2,10,11 The resulting
post-sinusoidal portal hypertension leads to the clinical syndrome of
SOS/VOD.2,5,6,11 In severe SOS/VOD, which is strongly associated with multi-organ
failure, mortality remains high.2,8,11 Early detection or prediction of SOS/VOD
could allow identification of patients who could benefit from prophylactic meas-
ures,3 and preliminary data show that pre-emptive treat-
ment with defibrotide might be effective,12 making tools
to predict SOS/VOD highly desirable.
Recently, a SOS/VOD clinical risk score (age, Karnofsky
status, sirolimus use, hepatitis B/C status, conditioning
regimen, disease type) has been published by the Center
for International Blood and Marrow Transplant Research
(CIBMTR).13 However, this score has not yet been validat-
ed outside of the CIBMTR database. In addition, it has
been suggested that serum biomarkers, including
microparticles and plasminogen activator inhibitor (PAI)-
1, may be useful to predict SOS/VOD,14-18 but validation
and clinical implementation of these non-routine bio-
markers will be difficult due to the lack of standardization. 
We had previously developed a standard biomarker
panel to assess endothelial dysfunction and activation: the
Endothelial Activation and Stress Index (EASIX). EASIX is
based on the simple formula “lactate dehydrogenase
(LDH) (U/L) * creatinine (mg/dL) / thrombocytes (109 cells
per L)” and thus calculated using three of the diagnostic
parameters of thrombotic microangiopathy (TMA),19
which is another endothelial complication after alloSCT.20
EASIX has also been shown to predict mortality of
patients with acute graft-versus-host disease (GvHD).19
With this background, the aim of the current study was
to test the SOS/VOD predictive capacity of EASIX com-




For this retrospective cohort analysis, a training cohort and a
validation cohort comprising consecutive adult patients who had
undergone alloSCT at two independent institutions were investi-
gated. Patients from the training cohort received alloSCT at the
Charité - Campus Virchow Clinic, Berlin, between January 2013
and December 2015. The validation cohort consisted of patients
who were allografted at the University of Heidelberg between
September 2001 and December 2009. Patients undergoing
alloSCT in Heidelberg after January 2010 received pravastatin and
ursodeoxycholic acid (UDA) as prophylaxis of endothelial compli-
cations after alloSCT. To reduce confounding influences, the vali-
dation cohort was restricted to the time period before the intro-
duction of pravastatin and UDA. The study was performed
according to the Declaration of Helsinki, with written informed
consent obtained by all eligible patients. The study has been
approved by the institutional review board of both institutions.
Definitions 
SOS/VOD was defined according to the 2016 European Group
for Blood and Marrow Transplantation (EBMT) criteria for
SOS/VOD diagnosis in adults.4 The disease score we applied for
the patients classifies the disease stage of the main diseases: acute
leukemia, myelodysplastic syndrome, chronic myeloid leukemia,
and non-Hodgkin lymphoma/multiple myeloma. The disease
stages are assigned according to the remission status at transplant
or the phases of chronic myeloid leukemia. The stages include
‘early disease stage' (0), ‘intermediate disease stage’ (1), and ‘late
stage disease’ (2).21
CIBMTR sinusoidal obstruction 
syndrome/veno-occlusive disease risk score
The SOS/VOD CIBMTR risk score has been established to
assess the risk of developing SOS/VOD after alloSCT.13 It incorpo-
rates age, hepatitis B/C serology, Karnofsky performance status,
use of sirolimus prophylaxis, disease, disease status at the time of
transplant, and conditioning regimen. It was developed using the
CIBMTR database.13 We used the ‘VOD Risk Calculator’22 and
recorded the probability of SOS/VOD development for each
patient in the two independent cohorts when possible.
EASIX score
The EASIX score was calculated using the formula: “LDH (U/L)
*creatinine (mg/dL) / thrombocytes (109 cells per L)” as described
previously, assessed at the day of alloSCT (EASIX-d0).19
Statistical analysis
The primary objective was prediction of SOS/VOD occurrence.
Primary analysis was performed for the binary endpoint “cumula-
tive incidence of SOS/VOD within 28 days after alloSCT” and the
time-to-event endpoint “time to VOD (TTV)” which is defined as
time from alloSCT to diagnosis of SOS/VOD. Secondary objec-
tives were the prediction of overall survival (OS) and time to non-
relapse mortality (NRM) measured from the day of alloSCT. TTV
and NRM were analyzed using competing event models. The
competing event for TTV is "non-SOS/VOD-mortality" defined as
time from alloSCT to death without prior SOS/VOD, whereas the
competing event for NRM is "time to relapse" defined as time
from alloSCT to relapse of disease. Further details on statistical
analyses are provided in the Online Supplementary Appendix.
Results
Patients' characteristics 
The training cohort and the validation cohort consisted
of 446 and 380 patients, respectively. The baseline charac-
teristics are presented in Table 1. The patient cohorts were
similar with regards to age, sex, conditioning regimen, and
SOS/VOD incidence. However, there were significant dif-
ferences in the categories donor type (more matched unre-
lated donors in the training cohort), underlying disease
(most frequent disease: acute myeloid leukemia, 51% and
27% in the training and validation cohort, respectively),
stem cell source (bone marrow used more frequently in
the validation cohort), and use of anti-thymocyte globulin
(ATG) (more commonly used in the training cohort).
EASIX-d0 and sinusoidal obstruction 
syndrome/veno-occlusive disease risk
SOS/VOD was diagnosed in 43 patients (9.6%, median
onset day [d] +9) in the training cohort and in 32 patients
(8.4%, median onset d +7) in the validation cohort. In the
training cohort, median EASIX-d0 in patients who later
went on to develop SOS/VOD was significantly higher
than in patients who did not develop SOS/VOD (40.26;
interquartile range [IQR] 14.72-80.38 vs. 16.06; IQR 6.00-
36.54, P<0.0001) (Figure 1A). These findings were con-
firmed in the validation cohort, where median EASIX-d0
in patients who subsequently developed SOS/VOD was
also significantly higher than in patients who did not
develop SOS/VOD (8.64; IQR 3.38-15.40 vs. 2.28; IQR
0.92-7.48, P<0.0001) (Figure 1B).
Increasing EASIX-d0 was significantly associated with
SOS/VOD incidence in the training cohort in both univari-
able (OR per log2 increase 1.39, 95%CI:1.18-1.66, P=0.0001)
and multivariable analysis with the CIBMTR score as con-
founder (incorporating information on 6 clinical variables)
EASIX predicts SOS/VOD after alloSCT 
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Table 1. Baseline characteristics of the three patient cohorts: Berlin (training), Heidelberg no statins/ursodeoxycholic acid (UDA) (validation), and
Heidelberg with statins/UDA.
                                                                          Berlin cohort              Heidelberg                 Heidelberg                     P                              P                              P
                                                                        (training cohort)           no statins/              with statins/            Berlin vs.                Berlin vs.               Heidelberg
                                                                               (n=446)                  UDA cohort               UDA cohort             Heidelberg               Heidelberg           no statins/UDA
                                                                                                         (validation cohort)            (n=359)            no statins/UDA      with statins/UDA       vs. Heidelberg
                                                                                                                 (n=380)                                                                                                     with statins/UDA
Date of alloSCT                                                          01/2013 – 12/2015         09/2001 – 01/2010         01/2010 – 12/2015                                                                                               
Age at transplant in years - median (range)             54 (18-75)                     50 (17-70)                     56 (19-75)                                                                                                     
Recipient sex (n, %)                                                                                                                                                                             0.67                              0.942                             0.764
    Female                                                                             172 (39)                         153 (40)                         140 (39)                                                                                                       
    Male                                                                                  274 (61)                         227 (60)                         219 (61)                                                                                                       
Donor sex (n, %)                                                                                                                                                                                  0.877                             0.437                             0.584
    Female                                                                             124 (28)                         121 (32)                         122 (34)                                                                                                       
    Male                                                                                  274 (61)                         259 (68)                         237 (66)                                                                                                       
    NA                                                                                       48 (11)                                                                                                                                                                                      
Donor (n, %)                                                                                                                                                                                         <0.001                            0,034                            <0.001
    Matched related donor                                                 88 (20)                          141 (37)                          94 (26)                                                                                                        
    Matched unrelated donor                                            263 (59)                         140 (37)                         196 (55)                                                                                                       
    Mismatched related donor                                             6 (1)                              14 (4)                             11 (3)                                                                                                         
    Mismatched unrelated donor                                      89 (20)                            85(22)                            58 (16)                                                                                                        
Disease (n, %)                                                                                                                                                                                      <0.001                          <0.001                          <0.001
    AML                                                                                   229 (51)                         101 (27)                         126 (35)                                                                                                       
    MDS/MPN                                                                         82 (18)                           53 (14)                           69 (19)                                                                                                        
    ALL                                                                                      35 (8)                            39 (10)                            20 (6)                                                                                                         
    Lymphoma                                                                         41 (9)                            96 (25)                          100 (28)                                                                                                       
    MM                                                                                      39 (9)                            75 (20)                           36 (10)                                                                                                        
    Other                                                                                  20 (4)                             16 (4)                              8 (2)                                                                                                          
Disease score (n, %)                                                                                                                                                                           0.012                            <0.001                          <0.001
    0                                                                                         142 (32)                         131 (34)                         122 (34)                                                                                                       
    1                                                                                          47 (11)                           65 (17)                          122 (34)                                                                                                       
    2                                                                                         248 (56)                         184 (48)                         115 (32)                                                                                                       
    NA                                                                                         9 (2)                                                                                                                                                                                        
Stem-cell source (n, %)                                                                                                                                                                     <0.001                          <0.001                            0.566
    Peripheral blood                                                            443 (99)                         351 (92)                         336 (94)                                                                                                       
    Bone marrow                                                                     2 (1)                              29 (8)                             23 (6)                                                                                                         
    NA                                                                                         1 (0)                                                                                                                                                                                        
Conditioning (n, %)                                                                                                                                                                              0.999                             0.055                             0.069
    RIC                                                                                     341 (76)                         291 (77)                         294 (82)                                                                                                       
    MAC                                                                                   105 (24)                          89 (23)                           64 (18)                                                                                                        
Use of ATG (n, %)                                                                                                                                                                                <0.001                          <0.001                          <0.001
    Yes                                                                                     399 (89)                         193 (51)                         259 (72)                                                                                                       
    No                                                                                       47 (11)                          187 (49)                         100 (28)                                                                                                       
SOS/VOD development (EBMT criteria)(n, %)                                                                                                                            0.472                            <0.001                          <0.001
    SOS/VOD                                                                           43 (10)                            32 (8)                              6 (2)                                                                                                          
    No SOS/VOD                                                                   401 (90)                         348 (92)                         353 (98)                                                                                                       
Onset of SOS/VOD (median, range)                  d+9 (d+3 to d+30)      d+8 (d0 to d+24)     d+10 (d+1 to d+17)                                                                                           
Median CIBMTR score (range, IQR)                                                                                                                                                                                                                              
    SOS/VOD                                                                        n=32, rest                    n=29, rest                      n=5, rest
                                                                                         of data NA: 1.51            of data NA: 1.9             of data NA: 1.7 
                                                                                     (0.56-4.48; 0.82-2.37)       (0.3-8.7; 1.4-3.1)          (0.7-3.7; 1.0-2.7)                                                                                               
    No SOS/VOD                                                                n=338, rest                  n=333, rest                   n=347, rest
                                                                                         of data NA: 1.01            of data NA: 1.2              of data NA: 1.0
                                                                                     (0.32-9.72; 0.76-1.80)     (0.4-20.6; 0.9-2.1)        (0.3-9.1; 0.8-1.7)                                                                                               
Median EASIX-d0 (range, IQR)                                                                                                                                                                                                                                        
    SOS/VOD                                                                        n=41, rest                    n=32, rest                       n=6 rest 
                                                                                        of data NA: 40.26:          of data NA: 8.6             of data NA: 7.4
                                                                                (5.23-865.06; 14.72-80.38) (0.2-41.0; 3.4-15.4)     (4.0-17.1; 5.8-14.8)                                                                                             
    No SOS/VOD                                                                n=376, rest                  n=348, rest                   n=353, rest
                                                                                        of data NA: 16.06           of data NA: 2.3              of data NA: 7.5
                                                                                    (0.38-575; 6.00-36.54)   (0.2-99.2; 0.9-7.5)    (0.2-195.8; 2.1-14.9)                                                                                     
SOS/VOD: sinusoidal obstruction syndrome/veno-occlusive disease; UDA: ursodeoxycholic acid; alloSCT: allogeneic stem cell transplantation; NA: not available; AML: acute myeloid leukemia;
MDS: myelodysplastic syndrome; ALL: acute lymphocytic leukemia; CLL: chronic lymphocytic leukemia; MPN: myeloproliferative neoplasms; CML: chronic myeloid leukemia; MM: multiple
myeloma; RIC: reduced intensity conditioning; MAC: myeloablative conditioning; ATG: anti-thymocyte globulin; KPS: Karnofsky Performance Score; IQR: interquartile range; CIBMTR: Center for
International Blood and Marrow Transplant Research; EBMT: European Group for Blood and Marrow Transplantation; EASIX-d0: EASIX assessed at the day of alloSCT; n: number; d: day. 
(OR per log2 increase 1.31, 95%CI:1.08-1.59, P=0.0067)
(Figure 2A). Similarly, EASIX-d0 was strongly associated
with the incidence of SOS/VOD in the validation cohort
(univariable analysis: OR per log2 increase 1.50, 95%CI:
1.22-1.88, P=0.0002; multivariable analysis: OR per log2
increase 1.57, 95%CI: 1.26-2.01, P=0.0001) (Figure 2B). 
Based on these data, we have created the EASIX-d0
SOS/VOD calculator for free public use (http://biostatis-
tics.dkfz.de/EASIX/).
Association of EASIX-d0 with overall survival and 
non-relapse mortality 
In the training cohort, EASIX-d0 was significantly asso-
ciated with OS and NRM in univariable analysis (OS: HR
per log2 increase 1.20, 95%CI: 1.12-1.29, P<0.0001; NRM:
cause-specific hazard ratio [CSHR] per log2 increase 1.25,
95%CI: 1.14-1.38, P<0.0001) (Figure 3A and C). Likewise,
EASIX-d0 was significantly associated with OS and NRM
in the validation cohort in univariable analysis (OS: HR
per log2 increase 1.10, 95%CI: 1.02-1.18, P=0.0124; NRM:
CSHR per log2 increase 1.18, 95%CI: 1.06-1.32, P=0.0024)
(Figure 3B and D).
Association of the CIBMTR clinical risk score with
sinusoidal obstruction syndrome/veno-occlusive 
disease incidence, overall survival and non-relapse
mortality
In the training cohort, a non-significant trend towards a
higher median CIBMTR score was observed in patients
who subsequently developed SOS/VOD as compared to
patients who did not develop SOS/VOD (1.51; IQR 0.82-
2.37 vs. 1.01; IQR 0.76-1.80, P=0.069). In the validation
cohort, the median CIBMTR score in patients with
SOS/VOD was significantly higher than that in patients
without SOS/VOD (1.92; IQR 1.44-3.09 vs. 1.20; IQR
0.89-2.15, P=0.00053). On time-to-event analysis, howev-
er, the association of the CIBMTR score with SOS/VOD
incidence was not statistically significant in the training
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Figure 1. Endothelial Activation and Stress Index (EASIX) assessed at the day of alloSCT (EASIX-d0) in patients without sinusoidal obstruction syndrome/veno-occlu-
sive disease (SOS/VOD) versus EASIX-d0 in patients with SOS/VOD. Box plot of EASIX-d0 in patients without SOS/VOD (No VOD) versus EASIX-d0 in patients with
SOS/VOD (VOD)) in (A) the training and (B) the validation cohort.
Figure 2. Time to sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD)  depending on Endothelial Activation and Stress Index (EASIX) assessed at
the day of alloSCT (EASIX-d0) quartiles. (A) Training and (B) validation cohort. SCT: stem cell transplantation.
 A                                                                                         B
 A                                                                                         B
cohort (univariable analysis: OR per log2 increase 1.19,
95%CI: 0.87-1.54, P=0.2288) (Figure 4A) nor in the valida-
tion cohort (univariable analysis: OR per log2 increase
1.07, 95%CI: 0.92-1.20, P=0.308) (Figure 4B). 
Brier score based on observed SOS/VOD incidence in
the training cohort (null model) is 0.0774 in the validation
cohort. Inclusion of EASIX-d0 leads to a reduction in the
quadratic prediction error (0.0735) of approximately 5%.
In contrast, Brier score of the CIBMTR score model
(0.0771) is similar to the Brier score of the null model. 
In both cohorts, the CIBMTR score was not predictive
of OS or NRM (univariable analysis, training cohort, OS:
HR per log2 increase 1.08, 95%CI: 0.95-1.22, P=0.2264;
NRM: CSHR per log2 increase 1.15, 95%CI: 1.00-1.33,
P=0.0565; validation cohort, OS: HR per log2 increase
1.03, 95%CI: 0.97-1.09, P=0.4126; NRM: CSHR per log2
increase 0.95, 95%CI: 0.84-1.08, P=0.4648). 
Effect of pravastatin/ursodeoxycholic acid on 
sinusoidal obstruction syndrome/veno-occlusive 
disease incidence 
Patients undergoing alloSCT in Heidelberg after January
2010 received pravastatin and UDA as routine prophylaxis
of endothelial complications after alloSCT. In this cohort
of 359 consecutive patients transplanted in Heidelberg
between January 2010 and December 2015, the SOS/VOD
incidence was significantly lower than in the training and
validation cohorts treated without endothelial prophylax-
is (1.7%, vs. 9.6% and 8.4%, P<0.0001) (Figure 5A). Next,
we focused on the effect of pravastatin/UDA prophylaxis
on SOS/VOD incidence, NRM and OS in a population at
increased risk for SOS/VOD, defined by the highest
EASIX-d0 quartile in each of the three cohorts. The
patient cohort at increased risk that received
pravastatin/UDA showed a significantly lower SOS/VOD
incidence (Figure 5B), lower NRM (Figure 5C), and higher
OS (Figure 5D)  compared to the high-risk patient popula-
tions in the training and validation cohorts.
Discussion
In this retrospective cohort analysis, EASIX-d0 was
found to be an independent predictor of SOS/VOD risk,
OS and NRM in adult patients receiving alloSCT. EASIX-
d0 constitutes the first validated biomarker for defining a
subpopulation of alloSCT recipients at high risk for
SOS/VOD. It consists of routine laboratory parameters
enabling easy implementation in any transplant center.
EASIX-d0 seems to be a readily available tool for stratify-
ing patients into high- and low-risk populations, which
could be useful to improve clinical management of
SOS/VOD, and for identifying patient subsets for clinical
trials on SOS/VOD prophylaxis. Outside of clinical stud-
S. Jiang et al.
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Figure 3. Univariable effect of Endothelial Activation and Stress Index (EASIX) assessed at the day of alloSCT (EASIX-d0) on overall survival (OS) and non-relapse
mortality (NRM). Univariable effect of EASIX-d0 on OS in (A) the training cohort and (B) the validation cohort. Univariable association of EASIX-d0 with NRM in (C) the
training cohort and (D) the validation cohort.
 A                                                                                            B
 C                                                                                            D
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Figure 4. Time to sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) depending on Center for International Blood and Marrow Transplant
Research (CIBMTR) score quartiles. (A) Training and (B) validation cohort. SCT: stem cell transplantation.
Figure 5. Effects of pravastatin/ursodeoxycholic acid prophylaxis (blue) compared to the training cohort (green) and the validation cohort (red). (A) Time to sinu-
soidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in the three cohorts. (B) Time to SOS/VOD in patients with the highest Endothelial Activation and
Stress Index (EASIX) assessed at the day of alloSCT (EASIX-d0) quartiles in the three cohorts. (C) Time to non-relapse mortality (NRM) in patients with the highest
EASIX-d0 quartile in the three cohorts. (D) Overall survival (OS) in patients with the highest EASIX-d0 quartile in the three cohorts. SCT: stem cell transplantation.
 A                                                                                         B
 A                                                                                         B
 C                                                                                         D
ies, patients with high EASIX-d0 scores might benefit
from closer monitoring of emerging clinical SOS/VOD
signs and early interventions. 
EASIX-d0 has to be put into perspective with the
CIBMTR SOS/VOD clinical risk score, which has been
recently described as a predictive tool to identify patients
at high risk of developing SOS/VOD.13 The CIBMTR score
has been established using a large sample from the
CIBMTR database and consists of select baseline parame-
ters which are partly fixed (age, hepatitis B/C serology,
Karnofsky performance score, diagnosis, disease status at
transplant) and partly subject to intervention (use of
sirolimus, conditioning regimen). It has been shown to be
predictive for SOS/VOD but not for NRM and OS.13 In the
present study, the CIBMTR score exhibited only a weak
association with SOS/VOD incidence and no association
with NRM or OS. One explanation for this discrepancy
might be that the two European cohorts investigated in
the current study differed in some respects from the
CIBMTR cohort. First, in vivo T-cell depletion with ATG
was administered in most patients in the two European
cohorts, whereas the majority of the CIBMTR patients did
not receive ATG for GvHD prophylaxis.13 Second, most
patients in our two cohorts were conditioned with
reduced intensity conditioning (RIC), whereas only a
minority of patients from the CIBMTR database received
an RIC regimen.13 Third, sirolimus was administered in
8% of the patients from the CIBMTR database,13 whereas
none of our patients received sirolimus prophylaxis. This
is relevant because sirolimus was a risk factor for
SOS/VOD development in the CIBMTR analysis. In addi-
tion, registry data might be prone to consistency deficits,
while we had immediate access to the primary data ensur-
ing the high quality of the data used in our study. Of note,
the CIBMTR score has been primarily validated in a large
population. We have validated the current EASIX-VOD
score in smaller cohorts. Therefore, further validation is
needed. The EBMT is currently conducting a prospective
non-interventional study on the value of the EASIX score
to predict alloSCT-related endothelial complications.
Furthermore, we expect that data from several retrospec-
tive cohorts in different centers will soon be available. 
Based on previous publications on the efficacy of UDA
and statins in the protection of the endothelium,23,24 the
Heidelberg alloSCT group decided to administer pravas-
tatin and UDA as prophylaxis for alloSCT recipients trans-
planted after January 2010. UDA is a synthetic bile acid
that reduces the incidence of SOS/VOD, and is associated
with less liver toxicity and better survival rates.3,25 Statins
have not been extensively studied for the prevention of
endothelial complications. However, its pleiotropic effects
include, besides the inhibition of cholesterol synthesis,
improving endothelial function, reducing oxidative stress
and inflammation, and decreasing thrombogenic proper-
ties.26,27 Statins may therefore be beneficial in the preven-
tion of endothelial complications. Accordingly, we
observed a reduction of endothelial post-transplant com-
plications, as previously shown in TMA20 and refractory
GvHD28 upon implementation of statin/UDA endothelial
prophylaxis. 
In the present study, the SOS/VOD incidence was
markedly reduced after the introduction of
pravastatin/UDA prophylaxis. These protective effects,
both in terms of SOS/VOD risk reduction and lower NRM
and overall mortality, were particularly pronounced in
patients with high EASIX-d0 scores, as compared to high-
risk patients who did not receive pravastatin/UDA. This
suggests that patients at high risk for SOS/VOD may ben-
efit most from prophylactic SOS/VOD strategies.  
Limitations of our study are its retrospective design and
the validation in only one independent cohort of patients
with similar patients' characteristics, which are typical for
adult European alloSCT transplant centers. Therefore, the
results cannot be extrapolated to pediatric alloSCT popu-
lations. Since EASIX-d0 is very easy to assess, any trans-
plant center now has the opportunity to evaluate its
potential in their respective patient population and we
hope that more data on different patient populations,
including pediatric patients or haploidentical transplanta-
tion, will soon be available. To facilitate this process, we
have created the EASIX-d0 SOS/VOD calculator for free
public use (http://biostatistics.dkfz.de/EASIX/).
In conclusion, EASIX-d0 seems to be an easy-to-use bio-
marker for identifying patient populations at high risk for
SOS/VOD, and thus could be a promising tool both for
clinical trials and tailored monitoring strategies.
Statin/UDA endothelial prophylaxis could be an option to
overcome the increased SOS/VOD risk indicated by high
EASIX-d0 scores. 
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